ascopubs.org

Prediction of recurrence in stage I EGFR mutation-positive NSCLC: Combination of CT appearance and selected co-occurring gene alterations by machine learning.

Analysis of outcomes in resected early-stage non-small cell lung cancer (NSCLC) with rare targetable driver mutations. Neoadjuvant hypofractionated radiotherapy combined with pembrolizumab plus ...
Healio

Study: Race-free eGFR equations may reclassify Black adults into more advanced CKD stages

Please provide your email address to receive an email when new articles are posted on . Of patients with CKD stages 3 to 5, 45.8% of Black adults were reclassified to more advanced stages. Overall, 44 ...
Medscape

'Outstanding' Results for Osimertinib in Unresectable Stage III EGFR+ NSCLC

CHICAGO — Osimertinib (Tagrisso) may soon have approvals across all stages of epidermal growth factor receptor (EGFR)–mutated non–small cell lung cancer (NSCLC). The third-generation EGFR tyrosine ...
News Medical

Study provides new hope for patients with stage III EGFR-mutant non-small cell lung cancer

Our study provides new hope for patients with stage III EGFR -mutant non-small cell lung cancer. utation and improve survival." Amin Nassar, hematology/oncology fellow at Yale Cancer Center About half ...
Monthly Prescribing Reference

Osimertinib Gets Priority Review for Stage III Unresectable EGFR-Mutated NSCLC

Results showed treatment with osimertinib reduced the risk of disease progression or death by 84% compared with placebo. The Food and Drug Administration (FDA) has granted Priority Review to the ...